Live Streaming of Demystifying Pyrazinamide Workshop–September 5 & 6

On September 5 and 6, 2012, the “Demystifying Pyrazinamide – Challenges and Opportunities” Workshop will be held at Johns Hopkins University and is sponsored by National Institute of Allergy and Infectious Diseases, Bill and Melinda Gates Foundation, Johns Hopkins University Center for AIDS Research, and the Stop TB Partnership Working Group on New Drugs. There will be live streaming available. The links for each day of the workshop are:

Wednesday, Sept 5:

Thursday, Sept 6:


Purpose: The workshop aims to highlight ongoing PZA research, provide overview of current knowledge, identify knowledge gaps, identify potential collaborations, establish priorities and strategies to achieve objectives, and perhaps identify more research funding.

The focus of the workshop is intended to improve the use of PZA in any way that makes sense in the context of combo therapy. As a single drug for treatment use, PZA is not relevant. But how it can be improved within combinations is the ultimate aim, including improved and rapid susceptibility testing.

Note: Presentations will be archived and made available to the public on a meeting page that can be accessed from the “Meetings” tab on the main menu at shortly after the conclusion of the workshop.

More News
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...
22 Oct 2020
On Thursday, October 21st, 2020, the U.S. Centers for Disease Control and Prevention's (CDC) TB Trials Consortium (TBTC) announced results from their Phase 3, open-label trial: Study 31/A5349. The clinical trial identified a 4-month drug regimen composed of high-dose rifapentine, moxyifloxacin,...